Table 2.
Patient demographic characteristics
| Concept Elicitation | Cognitive Debriefing | |
|---|---|---|
| Demographic Information | Mean (Range), years | |
| Age | 57.2 (41–76) | 63.30 (39–74) |
| Time since diagnosis | 2.3 (0.33–8) | 4.18 (0.50–18) |
| Time from first symptom to diagnosis | 2 (0.25–4) | – |
| N (%) | ||
| Gender | ||
| Male | 6 (60) | 5 (50) |
| Female | 4 (40) | 5 (50) |
| Region of U.S. Residence | ||
| South | 4 (40) | 0 (0) |
| Midwest | 3 (30) | 0 (0) |
| East Coast | 2 (20) | 10 (100) |
| West Coast | 1 (10) | 0 (0) |
| Education | ||
| Less than Bachelor’s degree | 4 (40) | 5 (50) |
| Bachelor’s degree | 3 (30) | 2 (20) |
| Post-graduate | 3 (30) | 3 (30) |
| Multiple Organ Involvement | ||
| Yes | 5 (50) | 4 (40) |
| No | 5 (50) | 6 (60) |
| Organs Affecteda | ||
| Heart | 6 (60) | 5 (50) |
| Kidney | 5 (50) | 6 (60) |
| Gastrointestinal Tract | 3 (30) | 0 (0) |
| Nervous System | 2 (20) | 1 (10) |
| Liver | 0 (0) | 1 (10) |
| Bladder | 0 (0) | 1 (10) |
| Remission Status | ||
| Full Remission | 5 (50) | 2 (20) |
| Partial Remission | 1 (10) | 3 (30) |
| Not in Remission | 4 (40) | 4 (40) |
| Unsure | 0 (0) | 1 (10) |
| Current Treatmenta | ||
| Bortezomib (Velcade) | 4 (40) | – |
| Dexamethasone | 3 (30) | – |
| Doxycycline | 2 (20) | – |
| Lenalidomide (Revlimid) | 2 (20) | – |
| Other | 2 (20) | – |
aPatients were able to select more than one option, so percentages exceed 100
– indicates that data were not collected for this variable